Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gain Therapeutics Inc
(NQ:
GANX
)
1.990
+0.150 (+8.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gain Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Why Is Nvni Group (NVNI) Stock Down 8% Today?
October 04, 2023
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger.
Via
InvestorPlace
Why Is Gain Therapeutics (GANX) Stock Moving Today?
October 04, 2023
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday.
Via
InvestorPlace
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
October 04, 2023
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Gain Therapeutics
June 12, 2023
Via
Benzinga
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
May 15, 2023
Via
Benzinga
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
September 25, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
September 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
September 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Where Gain Therapeutics Stands With Analysts
May 15, 2023
Via
Benzinga
Analyst Expectations for Gain Therapeutics's Future
May 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
September 12, 2023
Via
Benzinga
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Via
Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
--News Direct--
Via
News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,...
Via
TheNewswire.com
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
August 28, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 07, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
July 31, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 03, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 29, 2023
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 23, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 22, 2023
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 21, 2023
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
February 27, 2023
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
February 02, 2023
Gain to present new preclinical data on its lead programs in GBA1-related diseases
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.